Targeting STAT3 and STAT5 in Cancer

Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur...

Повний опис

Збережено в:

Бібліографічні деталі
Формат:	Online
Мова:	Англійська
Опубліковано:	MDPI - Multidisciplinary Digital Publishing Institute 2021
Предмети:	multiple myeloma STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor–immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
Онлайн доступ:	ONIX_20210501_9783039430369_821
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Targeting STAT3 and STAT5 in Cancer

Схожі ресурси: Targeting STAT3 and STAT5 in Cancer

Схожі ресурси